Current Environment: Production

Anne O'Donnell-Luria | Medical Services

Programs & Services

Languages

  • English

Anne O'Donnell-Luria | Education

Medical School

Columbia University Medical School

2011, New York, NY

Residency

Medical Genetics

Boston Combined Pediatrics Residency Program (BCRP)

2017, Boston, MA

Fellowship

Boston Children's Hospital

2016, Boston, MA

Anne O'Donnell-Luria | Certifications

  • American Board of Medical Genetics and Genomics (Clinical Genetics)
  • American Board of Medical Genetics and Genomics (Medical Biochemical Genetics)
  • American Board of Pediatrics (General)

Anne O'Donnell-Luria | Professional History

Dr. Anne O’Donnell-Luria is the Co-Director of the Broad Institute Center for Mendelian Genomics (CMG), she leads a team analyzing thousands of rare disease families to improve genetic diagnosis and novel disease gene discovery. Her research is focused on using large-scale genomics to understand the mechanisms of incomplete penetrance.

Dr. O’Donnell-Luria co-leads the EpiChroma clinic, A Genetics Clinic for Epigenetic and Chromatin Disorders, [2]http://epichromaclinic.com/. The EpiChroma clinic focuses on diagnosing and caring for children and families with disorders due to mutations in the DNA methylation or histone machinery. By working together with families, she hopes to improve patient management and increase research for these conditions, while educating providers and families about epigenetics and the associated conditions. She also sees patients with inborn errors of metabolism and other rare genetic conditions.

Dr. O’Donnell-Luria is trained in clinical genetics, biochemical genetics and pediatrics. She completed her MD/PhD training at Columbia University Medical School in New York. Her thesis research focused on the role of DNA methylation alterations in complex disease including cancer and neuropsychiatric disease. She became interested in rare disease during medical school, leading her to be the first to complete the Combined Pediatrics-Genetics Residency Training Program at Boston Children’s Hospital and Harvard Medical School. She further completed a Fellowship in Medical Biochemical Genetics at Boston Children’s Hospital.

Anne O'Donnell-Luria | Publications

  1. Functional associations of evolutionarily recent human genes exhibit sensitivity to the 3D genome landscape and disease. bioRxiv. 2024 Nov 22. View Functional associations of evolutionarily recent human genes exhibit sensitivity to the 3D genome landscape and disease. Abstract

  2. Neurodevelopmental disorders associated variants in ADAT3 disrupt the activity of the ADAT2/ADAT3 tRNA deaminase complex and impair neuronal migration. medRxiv. 2024 Nov 18. View Neurodevelopmental disorders associated variants in ADAT3 disrupt the activity of the ADAT2/ADAT3 tRNA deaminase complex and impair neuronal migration. Abstract

  3. Advancing long-read nanopore genome assembly and accurate variant calling for rare disease detection. medRxiv. 2024 Aug 22. View Advancing long-read nanopore genome assembly and accurate variant calling for rare disease detection. Abstract

  4. Assessment of the evidence yield for the calibrated PP3/BP4 computational recommendations. Genet Med. 2024 Nov; 26(11):101213. View Assessment of the evidence yield for the calibrated PP3/BP4 computational recommendations. Abstract

  5. Expanding the genetics and phenotypes of ocular congenital cranial dysinnervation disorders. Genet Med. 2024 Jul 17; 101216. View Expanding the genetics and phenotypes of ocular congenital cranial dysinnervation disorders. Abstract

  6. Pathogenic variants in KMT2C result in a neurodevelopmental disorder distinct from Kleefstra and Kabuki syndromes. Am J Hum Genet. 2024 Aug 08; 111(8):1626-1642. View Pathogenic variants in KMT2C result in a neurodevelopmental disorder distinct from Kleefstra and Kabuki syndromes. Abstract

  7. De novo variants in the RNU4-2 snRNA cause a frequent neurodevelopmental syndrome. Nature. 2024 Aug; 632(8026):832-840. View De novo variants in the RNU4-2 snRNA cause a frequent neurodevelopmental syndrome. Abstract

  8. Evaluating predictors of kinase activity of STK11 variants identified in primary human non-small cell lung cancers. Res Sq. 2024 Jul 02. View Evaluating predictors of kinase activity of STK11 variants identified in primary human non-small cell lung cancers. Abstract

  9. Improving transparency of computational tools for variant effect prediction. Nat Genet. 2024 Jul; 56(7):1324-1326. View Improving transparency of computational tools for variant effect prediction. Abstract

  10. Diagnosing missed cases of spinal muscular atrophy in genome, exome, and panel sequencing datasets. medRxiv. 2024 Jun 29. View Diagnosing missed cases of spinal muscular atrophy in genome, exome, and panel sequencing datasets. Abstract

  11. Exploring penetrance of clinically relevant variants in over 800,000 humans from the Genome Aggregation Database. bioRxiv. 2024 Jun 13. View Exploring penetrance of clinically relevant variants in over 800,000 humans from the Genome Aggregation Database. Abstract

  12. Genome Sequencing for Diagnosing Rare Diseases. N Engl J Med. 2024 Jun 06; 390(21):1985-1997. View Genome Sequencing for Diagnosing Rare Diseases. Abstract

  13. De novoTLK1 and MDM1 mutations in a patient with a neurodevelopmental disorder and immunodeficiency. iScience. 2024 Jun 21; 27(6):109984. View De novoTLK1 and MDM1 mutations in a patient with a neurodevelopmental disorder and immunodeficiency. Abstract

  14. The landscape of regional missense mutational intolerance quantified from 125,748 exomes. bioRxiv. 2024 May 03. View The landscape of regional missense mutational intolerance quantified from 125,748 exomes. Abstract

  15. Critical assessment of variant prioritization methods for rare disease diagnosis within the rare genomes project. Hum Genomics. 2024 04 29; 18(1):44. View Critical assessment of variant prioritization methods for rare disease diagnosis within the rare genomes project. Abstract

  16. Exome copy number variant detection, analysis, and classification in a large cohort of families with undiagnosed rare genetic disease. Am J Hum Genet. 2024 05 02; 111(5):863-876. View Exome copy number variant detection, analysis, and classification in a large cohort of families with undiagnosed rare genetic disease. Abstract

  17. Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone. Ann Clin Transl Neurol. 2024 May; 11(5):1250-1266. View Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone. Abstract

  18. Mono and biallelic variants in HCN2 cause severe neurodevelopmental disorders. medRxiv. 2024 Mar 22. View Mono and biallelic variants in HCN2 cause severe neurodevelopmental disorders. Abstract

  19. Digenic inheritance involving a muscle-specific protein kinase and the giant titin protein causes a skeletal muscle myopathy. Nat Genet. 2024 Mar; 56(3):395-407. View Digenic inheritance involving a muscle-specific protein kinase and the giant titin protein causes a skeletal muscle myopathy. Abstract

  20. Novel syndromic neurodevelopmental disorder caused by de novo deletion of CHASERR, a long noncoding RNA. medRxiv. 2024 Feb 07. View Novel syndromic neurodevelopmental disorder caused by de novo deletion of CHASERR, a long noncoding RNA. Abstract

  21. Recurring homozygous ACTN2 variant (p.Arg506Gly) causes a recessive myopathy. Ann Clin Transl Neurol. 2024 Mar; 11(3):629-640. View Recurring homozygous ACTN2 variant (p.Arg506Gly) causes a recessive myopathy. Abstract

  22. Author Correction: A genomic mutational constraint map using variation in 76,156 human genomes. Nature. 2024 Feb; 626(7997):E1. View Author Correction: A genomic mutational constraint map using variation in 76,156 human genomes. Abstract

  23. Heterozygous loss-of-function SMC3 variants are associated with variable growth and developmental features. HGG Adv. 2024 Apr 11; 5(2):100273. View Heterozygous loss-of-function SMC3 variants are associated with variable growth and developmental features. Abstract

  24. Narrowing the diagnostic gap: Genomes, episignatures, long-read sequencing, and health economic analyses in an exome-negative intellectual disability cohort. Genet Med. 2024 05; 26(5):101076. View Narrowing the diagnostic gap: Genomes, episignatures, long-read sequencing, and health economic analyses in an exome-negative intellectual disability cohort. Abstract

  25. A gene pathogenicity tool "GenePy" identifies missed biallelic diagnoses in the 100,000 Genomes Project. Genet Med. 2024 04; 26(4):101073. View A gene pathogenicity tool "GenePy" identifies missed biallelic diagnoses in the 100,000 Genomes Project. Abstract

  26. Author Correction: Genomic autopsy to identify underlying causes of pregnancy loss and perinatal death. Nat Med. 2024 Jan; 30(1):302. View Author Correction: Genomic autopsy to identify underlying causes of pregnancy loss and perinatal death. Abstract

  27. A Panel-Agnostic Strategy 'HiPPo' Improves Diagnostic Efficiency in the UK Genomic Medicine Service. Healthcare (Basel). 2023 Dec 15; 11(24). View A Panel-Agnostic Strategy 'HiPPo' Improves Diagnostic Efficiency in the UK Genomic Medicine Service. Abstract

  28. Inferring compound heterozygosity from large-scale exome sequencing data. Nat Genet. 2024 Jan; 56(1):152-161. View Inferring compound heterozygosity from large-scale exome sequencing data. Abstract

  29. A genomic mutational constraint map using variation in 76,156 human genomes. Nature. 2024 Jan; 625(7993):92-100. View A genomic mutational constraint map using variation in 76,156 human genomes. Abstract

  30. Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria. JAMA Neurol. 2023 09 01; 80(9):980-988. View Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria. Abstract

  31. Advanced variant classification framework reduces the false positive rate of predicted loss-of-function variants in population sequencing data. Am J Hum Genet. 2023 09 07; 110(9):1496-1508. View Advanced variant classification framework reduces the false positive rate of predicted loss-of-function variants in population sequencing data. Abstract

  32. Systematic evaluation of genome sequencing for the diagnostic assessment of autism spectrum disorder and fetal structural anomalies. Am J Hum Genet. 2023 09 07; 110(9):1454-1469. View Systematic evaluation of genome sequencing for the diagnostic assessment of autism spectrum disorder and fetal structural anomalies. Abstract

  33. Beyond the exome: What's next in diagnostic testing for Mendelian conditions. Am J Hum Genet. 2023 08 03; 110(8):1229-1248. View Beyond the exome: What's next in diagnostic testing for Mendelian conditions. Abstract

  34. Advancing Understanding of Inequities in Rare Disease Genomics. Clin Ther. 2023 08; 45(8):745-753. View Advancing Understanding of Inequities in Rare Disease Genomics. Abstract

  35. DNM1L variant presenting as adolescent-onset sensory neuronopathy, spasticity, dystonia, and ataxia. J Pediatr Neurol. 2023 Dec; 21(6):475-478. View DNM1L variant presenting as adolescent-onset sensory neuronopathy, spasticity, dystonia, and ataxia. Abstract

  36. Classical phenylketonuria presenting as maternal PKU syndrome in the offspring of an intellectually normal woman. JIMD Rep. 2023 Sep; 64(5):312-316. View Classical phenylketonuria presenting as maternal PKU syndrome in the offspring of an intellectually normal woman. Abstract

  37. Phenotype and genetic analysis of data collected within the first year of NeuroDev. Neuron. 2023 09 20; 111(18):2800-2810.e5. View Phenotype and genetic analysis of data collected within the first year of NeuroDev. Abstract

  38. Rare penetrant mutations confer severe risk of common diseases. Science. 2023 06 02; 380(6648):eabo1131. View Rare penetrant mutations confer severe risk of common diseases. Abstract

  39. The landscape of tolerated genetic variation in humans and primates. Science. 2023 06 02; 380(6648):eabn8153. View The landscape of tolerated genetic variation in humans and primates. Abstract

  40. First-Tier Next Generation Sequencing for Newborn Screening: An Important Role for Biochemical Second-Tier Testing. Genet Med Open. 2023; 1(1). View First-Tier Next Generation Sequencing for Newborn Screening: An Important Role for Biochemical Second-Tier Testing. Abstract

  41. LHX2 haploinsufficiency causes a variable neurodevelopmental disorder. Genet Med. 2023 07; 25(7):100839. View LHX2 haploinsufficiency causes a variable neurodevelopmental disorder. Abstract

  42. National Human Genome Research Institute Genomic Data Science Analysis, Visualization, and Informatics Lab-Space: Reaching out to Clinicians. Circ Genom Precis Med. 2023 06; 16(3):275-276. View National Human Genome Research Institute Genomic Data Science Analysis, Visualization, and Informatics Lab-Space: Reaching out to Clinicians. Abstract

  43. Untargeted metabolomics profiling in pediatric patients and adult populations indicates a connection between lipid imbalance and epilepsy. medRxiv. 2023 Mar 30. View Untargeted metabolomics profiling in pediatric patients and adult populations indicates a connection between lipid imbalance and epilepsy. Abstract

  44. Transcriptome and Genome Analysis Uncovers a DMD Structural Variant: A Case Report. Neurol Genet. 2023 Apr; 9(2):e200064. View Transcriptome and Genome Analysis Uncovers a DMD Structural Variant: A Case Report. Abstract

  45. Variants in DTNA cause a mild, dominantly inherited muscular dystrophy. Acta Neuropathol. 2023 04; 145(4):479-496. View Variants in DTNA cause a mild, dominantly inherited muscular dystrophy. Abstract

  46. Interpreting variants in genes affected by clonal hematopoiesis in population data. Hum Genet. 2024 Apr; 143(4):545-549. View Interpreting variants in genes affected by clonal hematopoiesis in population data. Abstract

  47. Bi-allelic TTI1 variants cause an autosomal-recessive neurodevelopmental disorder with microcephaly. Am J Hum Genet. 2023 03 02; 110(3):499-515. View Bi-allelic TTI1 variants cause an autosomal-recessive neurodevelopmental disorder with microcephaly. Abstract

  48. Genomic autopsy to identify underlying causes of pregnancy loss and perinatal death. Nat Med. 2023 01; 29(1):180-189. View Genomic autopsy to identify underlying causes of pregnancy loss and perinatal death. Abstract

  49. Targeting de novo loss-of-function variants in constrained disease genes improves diagnostic rates in the 100,000 Genomes Project. Hum Genet. 2023 Mar; 142(3):351-362. View Targeting de novo loss-of-function variants in constrained disease genes improves diagnostic rates in the 100,000 Genomes Project. Abstract

  50. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. Am J Hum Genet. 2022 12 01; 109(12):2163-2177. View Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. Abstract

  51. Developmental dynamics of RNA translation in the human brain. Nat Neurosci. 2022 10; 25(10):1353-1365. View Developmental dynamics of RNA translation in the human brain. Abstract

  52. Response to Ramos et al. Genet Med. 2022 Dec; 24(12):2593-2594. View Response to Ramos et al. Abstract

  53. Wide range of phenotypic severity in individuals with late truncations unique to the predominant CDKL5 transcript in the brain. Am J Med Genet A. 2022 12; 188(12):3516-3524. View Wide range of phenotypic severity in individuals with late truncations unique to the predominant CDKL5 transcript in the brain. Abstract

  54. Recommendations for clinical interpretation of variants found in non-coding regions of the genome. Genome Med. 2022 07 19; 14(1):73. View Recommendations for clinical interpretation of variants found in non-coding regions of the genome. Abstract

  55. Diagnostic capabilities of nanopore long-read sequencing in muscular dystrophy. Ann Clin Transl Neurol. 2022 08; 9(8):1302-1309. View Diagnostic capabilities of nanopore long-read sequencing in muscular dystrophy. Abstract

  56. A gene-to-patient approach uplifts novel disease gene discovery and identifies 18 putative novel disease genes. Genet Med. 2022 08; 24(8):1697-1707. View A gene-to-patient approach uplifts novel disease gene discovery and identifies 18 putative novel disease genes. Abstract

  57. seqr: A web-based analysis and collaboration tool for rare disease genomics. Hum Mutat. 2022 06; 43(6):698-707. View seqr: A web-based analysis and collaboration tool for rare disease genomics. Abstract

  58. Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology. Am J Psychiatry. 2022 03; 179(3):189-203. View Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology. Abstract

  59. Recurrent de novo missense variants across multiple histone H4 genes underlie a neurodevelopmental syndrome. Am J Hum Genet. 2022 04 07; 109(4):750-758. View Recurrent de novo missense variants across multiple histone H4 genes underlie a neurodevelopmental syndrome. Abstract

  60. Centers for Mendelian Genomics: A decade of facilitating gene discovery. Genet Med. 2022 04; 24(4):784-797. View Centers for Mendelian Genomics: A decade of facilitating gene discovery. Abstract

  61. Recessive variants in COL25A1 gene as novel cause of arthrogryposis multiplex congenita with ocular congenital cranial dysinnervation disorder. Hum Mutat. 2022 04; 43(4):487-498. View Recessive variants in COL25A1 gene as novel cause of arthrogryposis multiplex congenita with ocular congenital cranial dysinnervation disorder. Abstract

  62. Delineation of a novel neurodevelopmental syndrome associated with PAX5 haploinsufficiency. Hum Mutat. 2022 04; 43(4):461-470. View Delineation of a novel neurodevelopmental syndrome associated with PAX5 haploinsufficiency. Abstract

  63. Mendelian etiologies identified with whole exome sequencing in cerebral palsy. Ann Clin Transl Neurol. 2022 02; 9(2):193-205. View Mendelian etiologies identified with whole exome sequencing in cerebral palsy. Abstract

  64. Variant interpretation using population databases: Lessons from gnomAD. Hum Mutat. 2022 08; 43(8):1012-1030. View Variant interpretation using population databases: Lessons from gnomAD. Abstract

  65. Lessons learnt from multifaceted diagnostic approaches to the first 150 families in Victoria's Undiagnosed Diseases Program. J Med Genet. 2022 08; 59(8):748-758. View Lessons learnt from multifaceted diagnostic approaches to the first 150 families in Victoria's Undiagnosed Diseases Program. Abstract

  66. Novel variants in KAT6B spectrum of disorders expand our knowledge of clinical manifestations and molecular mechanisms. Mol Genet Genomic Med. 2021 10; 9(10):e1809. View Novel variants in KAT6B spectrum of disorders expand our knowledge of clinical manifestations and molecular mechanisms. Abstract

  67. Addendum: The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2021 09; 597(7874):E3-E4. View Addendum: The mutational constraint spectrum quantified from variation in 141,456 humans. Abstract

  68. O'Donnell-Luria-Rodan syndrome: description of a second multinational cohort and refinement of the phenotypic spectrum. J Med Genet. 2022 07; 59(7):697-705. View O'Donnell-Luria-Rodan syndrome: description of a second multinational cohort and refinement of the phenotypic spectrum. Abstract

  69. Unique variants in CLCN3, encoding an endosomal anion/proton exchanger, underlie a spectrum of neurodevelopmental disorders. Am J Hum Genet. 2021 08 05; 108(8):1450-1465. View Unique variants in CLCN3, encoding an endosomal anion/proton exchanger, underlie a spectrum of neurodevelopmental disorders. Abstract

  70. Strategies to Uplift Novel Mendelian Gene Discovery for Improved Clinical Outcomes. Front Genet. 2021; 12:674295. View Strategies to Uplift Novel Mendelian Gene Discovery for Improved Clinical Outcomes. Abstract

  71. Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. Nat Commun. 2021 06 09; 12(1):3505. View Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. Abstract

  72. Familial thrombocytopenia due to a complex structural variant resulting in a WAC-ANKRD26 fusion transcript. J Exp Med. 2021 06 07; 218(6). View Familial thrombocytopenia due to a complex structural variant resulting in a WAC-ANKRD26 fusion transcript. Abstract

  73. A form of muscular dystrophy associated with pathogenic variants in JAG2. Am J Hum Genet. 2021 Jun 03; 108(6):1164. View A form of muscular dystrophy associated with pathogenic variants in JAG2. Abstract

  74. Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach. J Allergy Clin Immunol. 2022 01; 149(1):379-387. View Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach. Abstract

  75. A form of muscular dystrophy associated with pathogenic variants in JAG2. Am J Hum Genet. 2021 05 06; 108(5):840-856. View A form of muscular dystrophy associated with pathogenic variants in JAG2. Abstract

  76. Novel variants in TUBA1A cause congenital fibrosis of the extraocular muscles with or without malformations of cortical brain development. Eur J Hum Genet. 2021 05; 29(5):816-826. View Novel variants in TUBA1A cause congenital fibrosis of the extraocular muscles with or without malformations of cortical brain development. Abstract

  77. Author Correction: Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes. Nat Commun. 2021 Feb 02; 12(1):827. View Author Correction: Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes. Abstract

  78. Author Correction: Characterising the loss-of-function impact of 5' untranslated region variants in 15,708 individuals. Nat Commun. 2021 Feb 02; 12(1):839. View Author Correction: Characterising the loss-of-function impact of 5' untranslated region variants in 15,708 individuals. Abstract

  79. Author Correction: The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2021 Feb; 590(7846):E53. View Author Correction: The mutational constraint spectrum quantified from variation in 141,456 humans. Abstract

  80. Author Correction: Transcript expression-aware annotation improves rare variant interpretation. Nature. 2021 Feb; 590(7846):E54. View Author Correction: Transcript expression-aware annotation improves rare variant interpretation. Abstract

  81. Author Correction: A structural variation reference for medical and population genetics. Nature. 2021 Feb; 590(7846):E55. View Author Correction: A structural variation reference for medical and population genetics. Abstract

  82. De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis. Am J Hum Genet. 2021 02 04; 108(2):357-367. View De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis. Abstract

  83. Alternative genomic diagnoses for individuals with a clinical diagnosis of Dubowitz syndrome. Am J Med Genet A. 2021 01; 185(1):119-133. View Alternative genomic diagnoses for individuals with a clinical diagnosis of Dubowitz syndrome. Abstract

  84. Neurogenetic fetal akinesia and arthrogryposis: genetics, expanding genotype-phenotypes and functional genomics. J Med Genet. 2021 09; 58(9):609-618. View Neurogenetic fetal akinesia and arthrogryposis: genetics, expanding genotype-phenotypes and functional genomics. Abstract

  85. Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes. Nat Commun. 2020 05 27; 11(1):2539. View Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes. Abstract

  86. Characterising the loss-of-function impact of 5' untranslated region variants in 15,708 individuals. Nat Commun. 2020 05 27; 11(1):2523. View Characterising the loss-of-function impact of 5' untranslated region variants in 15,708 individuals. Abstract

  87. A structural variation reference for medical and population genetics. Nature. 2020 05; 581(7809):444-451. View A structural variation reference for medical and population genetics. Abstract

  88. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020 05; 581(7809):434-443. View The mutational constraint spectrum quantified from variation in 141,456 humans. Abstract

  89. Transcript expression-aware annotation improves rare variant interpretation. Nature. 2020 05; 581(7809):452-458. View Transcript expression-aware annotation improves rare variant interpretation. Abstract

  90. Phenotypic spectrum and transcriptomic profile associated with germline variants in TRAF7. Genet Med. 2020 07; 22(7):1215-1226. View Phenotypic spectrum and transcriptomic profile associated with germline variants in TRAF7. Abstract

  91. Apcdd1 is a dual BMP/Wnt inhibitor in the developing nervous system and skin. Dev Biol. 2020 08 01; 464(1):71-87. View Apcdd1 is a dual BMP/Wnt inhibitor in the developing nervous system and skin. Abstract

  92. Identification of pathogenic variant enriched regions across genes and gene families. Genome Res. 2020 01; 30(1):62-71. View Identification of pathogenic variant enriched regions across genes and gene families. Abstract

  93. Characterization of Prevalence and Health Consequences of Uniparental Disomy in Four Million Individuals from the General Population. Am J Hum Genet. 2019 11 07; 105(5):921-932. View Characterization of Prevalence and Health Consequences of Uniparental Disomy in Four Million Individuals from the General Population. Abstract

  94. Improving the Understanding of Genetic Variants in Rare Disease With Large-scale Reference Populations. JAMA. 2019 Oct 01; 322(13):1305-1306. View Improving the Understanding of Genetic Variants in Rare Disease With Large-scale Reference Populations. Abstract

  95. Genome Sequencing Identifies the Pathogenic Variant Missed by Prior Testing in an Infant with Marfan Syndrome. J Pediatr. 2019 10; 213:235-240. View Genome Sequencing Identifies the Pathogenic Variant Missed by Prior Testing in an Infant with Marfan Syndrome. Abstract

  96. Heterozygous Variants in KMT2E Cause a Spectrum of Neurodevelopmental Disorders and Epilepsy. Am J Hum Genet. 2019 06 06; 104(6):1210-1222. View Heterozygous Variants in KMT2E Cause a Spectrum of Neurodevelopmental Disorders and Epilepsy. Abstract

  97. Unique bioinformatic approach and comprehensive reanalysis improve diagnostic yield of clinical exomes. Eur J Hum Genet. 2019 09; 27(9):1398-1405. View Unique bioinformatic approach and comprehensive reanalysis improve diagnostic yield of clinical exomes. Abstract

  98. The Genetic Landscape of Diamond-Blackfan Anemia. Am J Hum Genet. 2019 Feb 07; 104(2):356. View The Genetic Landscape of Diamond-Blackfan Anemia. Abstract

  99. Insights into genetics, human biology and disease gleaned from family based genomic studies. Genet Med. 2019 04; 21(4):798-812. View Insights into genetics, human biology and disease gleaned from family based genomic studies. Abstract

  100. Using High-Resolution Variant Frequencies Empowers Clinical Genome Interpretation and Enables Investigation of Genetic Architecture. Am J Hum Genet. 2019 01 03; 104(1):187-190. View Using High-Resolution Variant Frequencies Empowers Clinical Genome Interpretation and Enables Investigation of Genetic Architecture. Abstract

  101. Reply to 'Selective effects of heterozygous protein-truncating variants'. Nat Genet. 2019 01; 51(1):3-4. View Reply to 'Selective effects of heterozygous protein-truncating variants'. Abstract

  102. The Genetic Landscape of Diamond-Blackfan Anemia. Am J Hum Genet. 2018 12 06; 103(6):930-947. View The Genetic Landscape of Diamond-Blackfan Anemia. Abstract

  103. matchbox: An open-source tool for patient matching via the Matchmaker Exchange. Hum Mutat. 2018 12; 39(12):1827-1834. View matchbox: An open-source tool for patient matching via the Matchmaker Exchange. Abstract

  104. Megaloblastic Anemia Progressing to Severe Thrombotic Microangiopathy in Patients with Disordered Vitamin B12 Metabolism: Case Reports and Literature Review. J Pediatr. 2018 11; 202:315-319.e2. View Megaloblastic Anemia Progressing to Severe Thrombotic Microangiopathy in Patients with Disordered Vitamin B12 Metabolism: Case Reports and Literature Review. Abstract

  105. Utility of rapid whole-exome sequencing in the diagnosis of Niemann-Pick disease type C presenting with fetal hydrops and acute liver failure. Cold Spring Harb Mol Case Stud. 2017 Nov; 3(6). View Utility of rapid whole-exome sequencing in the diagnosis of Niemann-Pick disease type C presenting with fetal hydrops and acute liver failure. Abstract

  106. ClinVar data parsing. Wellcome Open Res. 2017; 2:33. View ClinVar data parsing. Abstract

  107. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med. 2017 10; 19(10):1151-1158. View Using high-resolution variant frequencies to empower clinical genome interpretation. Abstract

  108. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci Transl Med. 2017 04 19; 9(386). View Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Abstract

  109. Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature. 2017 04 12; 544(7649):235-239. View Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Abstract

  110. Estimating the selective effects of heterozygous protein-truncating variants from human exome data. Nat Genet. 2017 May; 49(5):806-810. View Estimating the selective effects of heterozygous protein-truncating variants from human exome data. Abstract

  111. Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome. Hum Mutat. 2017 05; 38(5):517-523. View Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome. Abstract

  112. Brain MRS glutamine as a biomarker to guide therapy of hyperammonemic coma. Mol Genet Metab. 2017 05; 121(1):9-15. View Brain MRS glutamine as a biomarker to guide therapy of hyperammonemic coma. Abstract

  113. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016 08 18; 536(7616):285-91. View Analysis of protein-coding genetic variation in 60,706 humans. Abstract

  114. A Clinician's perspective on clinical exome sequencing. Hum Genet. 2016 06; 135(6):643-54. View A Clinician's perspective on clinical exome sequencing. Abstract

  115. Health and population effects of rare gene knockouts in adult humans with related parents. Science. 2016 Apr 22; 352(6284):474-7. View Health and population effects of rare gene knockouts in adult humans with related parents. Abstract

  116. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016 Jan 20; 8(322):322ra9. View Quantifying prion disease penetrance using large population control cohorts. Abstract

  117. Mutations in ARID2 are associated with intellectual disabilities. Neurogenetics. 2015 Oct; 16(4):307-14. View Mutations in ARID2 are associated with intellectual disabilities. Abstract

  118. Turner syndrome: update on biology and management across the life span. Curr Opin Endocrinol Diabetes Obes. 2015 Feb; 22(1):65-72. View Turner syndrome: update on biology and management across the life span. Abstract

  119. Methylation Abnormalities in Mammary Carcinoma: The Methylation Suicide Hypothesis. J Cancer Ther. 2014 Dec 01; 5(14):1311-1324. View Methylation Abnormalities in Mammary Carcinoma: The Methylation Suicide Hypothesis. Abstract

  120. Increased DNA methylation in the suicide brain. Dialogues Clin Neurosci. 2014 Sep; 16(3):430-8. View Increased DNA methylation in the suicide brain. Abstract

  121. Age-related sperm DNA methylation changes are transmitted to offspring and associated with abnormal behavior and dysregulated gene expression. Mol Psychiatry. 2015 Aug; 20(8):995-1001. View Age-related sperm DNA methylation changes are transmitted to offspring and associated with abnormal behavior and dysregulated gene expression. Abstract

  122. MethylomeDB: a database of DNA methylation profiles of the brain. Nucleic Acids Res. 2012 Jan; 40(Database issue):D1245-9. View MethylomeDB: a database of DNA methylation profiles of the brain. Abstract

  123. Role of CpG context and content in evolutionary signatures of brain DNA methylation. Epigenetics. 2011 Nov; 6(11):1308-18. View Role of CpG context and content in evolutionary signatures of brain DNA methylation. Abstract

  124. Chromatin and sequence features that define the fine and gross structure of genomic methylation patterns. Genome Res. 2010 Jul; 20(7):972-80. View Chromatin and sequence features that define the fine and gross structure of genomic methylation patterns. Abstract

  125. Mammalian cytosine methylation at a glance. J Cell Sci. 2009 Aug 15; 122(Pt 16):2787-91. View Mammalian cytosine methylation at a glance. Abstract

  126. Hyperconserved CpG domains underlie Polycomb-binding sites. Proc Natl Acad Sci U S A. 2007 Mar 27; 104(13):5521-6. View Hyperconserved CpG domains underlie Polycomb-binding sites. Abstract

  127. Solvent isotope effects on alpha-glucosidase. Biochim Biophys Acta. 2004 Dec 01; 1703(1):63-7. View Solvent isotope effects on alpha-glucosidase. Abstract

  128. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res. 2002 Aug 15; 62(16):4588-91. View Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Abstract

  129. KMT2E-Related Neurodevelopmental Disorder. GeneReviews®. 1993. View KMT2E-Related Neurodevelopmental Disorder Abstract

BESbswy